BACKGROUND AND OBJECTIVES: Clinical heart failure (HF) is associated with CKD and faster rates of kidney function decline. Whether subclinical abnormalities of cardiac structure are associated with faster kidney function decline is not known. The association between cardiac concentricity and kidney function decline was evaluated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a longitudinal study of 3866 individuals from the Multi-Ethnic Study of Atherosclerosis (2000-2007) who were free of clinical cardiovascular disease, with an estimated GFR (eGFR) ≥60 ml/min per 1.73 m(2) at baseline and 5 years of follow-up. Concentricity, a measurement of abnormal cardiac size, was assessed by magnetic resonance imaging and evaluated as a continuous measurement and in quartiles. GFR was estimated by creatinine (eGFRcr) and cystatin C (eGFRcys). The association of concentricity with annual eGFR decline, incident CKD, and rapid kidney function decline (>5% per year) was investigated using linear mixed models as well as Poisson and logistic regression, respectively. Analyses adjusted for demographics, BP, diabetes, and inflammatory markers. RESULTS: Median decline was -0.8 (interquartile range, -3.1, -0.5) by eGFRcr. Compared with the lowest quartile of concentricity, persons in the highest quartile had an additional 21% (9%-32%) decline in mean eGFRcr in fully adjusted models. Concentricity was also associated with incident CKD and with rapid kidney function decline after adjustment. CONCLUSIONS: Subclinical abnormalities in cardiac structure are associated with longitudinal kidney function decline independent of diabetes and hypertension. Future studies should examine mechanisms to explain these associations.
BACKGROUND AND OBJECTIVES: Clinical heart failure (HF) is associated with CKD and faster rates of kidney function decline. Whether subclinical abnormalities of cardiac structure are associated with faster kidney function decline is not known. The association between cardiac concentricity and kidney function decline was evaluated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a longitudinal study of 3866 individuals from the Multi-Ethnic Study of Atherosclerosis (2000-2007) who were free of clinical cardiovascular disease, with an estimated GFR (eGFR) ≥60 ml/min per 1.73 m(2) at baseline and 5 years of follow-up. Concentricity, a measurement of abnormal cardiac size, was assessed by magnetic resonance imaging and evaluated as a continuous measurement and in quartiles. GFR was estimated by creatinine (eGFRcr) and cystatin C (eGFRcys). The association of concentricity with annual eGFR decline, incident CKD, and rapid kidney function decline (>5% per year) was investigated using linear mixed models as well as Poisson and logistic regression, respectively. Analyses adjusted for demographics, BP, diabetes, and inflammatory markers. RESULTS: Median decline was -0.8 (interquartile range, -3.1, -0.5) by eGFRcr. Compared with the lowest quartile of concentricity, persons in the highest quartile had an additional 21% (9%-32%) decline in mean eGFRcr in fully adjusted models. Concentricity was also associated with incident CKD and with rapid kidney function decline after adjustment. CONCLUSIONS: Subclinical abnormalities in cardiac structure are associated with longitudinal kidney function decline independent of diabetes and hypertension. Future studies should examine mechanisms to explain these associations.
Authors: J S Gottdiener; A M Arnold; G P Aurigemma; J F Polak; R P Tracy; D W Kitzman; J M Gardin; J E Rutledge; R C Boineau Journal: J Am Coll Cardiol Date: 2000-05 Impact factor: 24.094
Authors: Linda F Fried; Michael G Shlipak; Casey Crump; Anthony J Bleyer; John S Gottdiener; Richard A Kronmal; Lewis H Kuller; Anne B Newman Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: Carmen A Peralta; Kathryn L Adeney; Michael G Shlipak; David Jacobs; Daniel Duprez; David Bluemke; Joseph Polak; Bruce Psaty; Bryan R Kestenbaum Journal: Am J Epidemiol Date: 2009-11-30 Impact factor: 4.897
Authors: Michael G Shlipak; Ronit Katz; Bryan Kestenbaum; David Siscovick; Linda Fried; Anne Newman; Dena Rifkin; Mark J Sarnak Journal: J Am Soc Nephrol Date: 2009-11-05 Impact factor: 10.121
Authors: Carmen A Peralta; Ronit Katz; Magdalena Madero; Mark Sarnak; Holly Kramer; Michael H Criqui; Michael G Shlipak Journal: Am J Epidemiol Date: 2009-01-08 Impact factor: 4.897
Authors: Michael G Shlipak; Ronit Katz; Bryan Kestenbaum; Linda F Fried; David Siscovick; Mark J Sarnak Journal: Atherosclerosis Date: 2008-08-26 Impact factor: 5.162
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Leila R Zelnick; Ronit Katz; Bessie A Young; Adolfo Correa; Bryan R Kestenbaum; Ian H de Boer; Nisha Bansal Journal: Am J Kidney Dis Date: 2017-01-28 Impact factor: 8.860
Authors: Todd H Driver; Michael G Shlipak; Ronit Katz; Leonard Goldenstein; Mark J Sarnak; Andrew N Hoofnagle; David S Siscovick; Bryan Kestenbaum; Ian H de Boer; Joachim H Ix Journal: Am J Kidney Dis Date: 2014-06-18 Impact factor: 8.860
Authors: Meyeon Park; Eric Vittinghoff; Michael G Shlipak; Rakesh Mishra; Mary Whooley; Nisha Bansal Journal: Am Heart J Date: 2014-10-14 Impact factor: 4.749
Authors: Nisha Bansal; Ronit Katz; Lorien Dalrymple; Ian de Boer; Christopher DeFilippi; Bryan Kestenbaum; Meyeon Park; Mark Sarnak; Stephen Seliger; Michael Shlipak Journal: Clin J Am Soc Nephrol Date: 2015-01-20 Impact factor: 8.237
Authors: Matthew Denker; Suzanne Boyle; Amanda H Anderson; Lawrence J Appel; Jing Chen; Jeffrey C Fink; John Flack; Alan S Go; Edward Horwitz; Chi-Yuan Hsu; John W Kusek; James P Lash; Sankar Navaneethan; Akinlolu O Ojo; Mahboob Rahman; Susan P Steigerwalt; Raymond R Townsend; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2015-08-11 Impact factor: 8.237